ACP
STRO icon

Acuta Capital Partners’s Sutro Biopharma STRO Stock Holding History

Acuta Capital Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.71M Buy
269,425
+201,974
+299% +$3.65M 4.73% 6
2025
Q4 		$780K Buy
+67,451
New +$640K 0.53% 24
2019
Q2 		– Sell
-4,550
Closed -$518K – 38
2019
Q1 		$518K Hold
4,550
– – 0.25% 30
2018
Q4 		$410K Buy
+4,550
New +$549K 0.31% 19

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acuta Capital Partners's STRO Position: Q1 2026 in Review

Acuta Capital Partners increased its Sutro Biopharma (STRO) stake by 299% in Q1 2026, buying an estimated $3.65M and bringing the position to 269,425 shares worth $6.71M. The position accounts for 4.73% of the portfolio, ranked #6.

Acuta Capital Partners first reported a position in STRO in Q4 2018 and has held it in 4 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Acuta Capital Partners held 269,425 shares of Sutro Biopharma worth $6.71M as of Q1 2026.
  • Acuta Capital Partners bought 201,974 Sutro Biopharma shares in Q1 2026, an estimated $3.65M.
  • Sutro Biopharma made up 4.73% of Acuta Capital Partners's portfolio in Q1 2026, its #6 holding.
  • Acuta Capital Partners first reported a position in Sutro Biopharma in Q4 2018 and has held it in 4 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.